Post-licensure Safety of the Live-Attenuated Chikungunya Vaccine in Older Adults: An Integrative Review With Implications for Brazil

Post-licensure reports of serious adverse events in older adults have raised concern about the live-attenuated chikungunya vaccine, which is being used in a pilot program in Brazil. This integrative review synthesizes the post-licensure safety evidence for this vaccine in older adults and discusses what it means for Brazilian policy. A single database, PubMed, was searched on 8 October 2026 for records published from 2023 onward (70 records identified and 30 included). Regulatory documents and press reports were consulted separately as supplementary sources and are not counted among the 30 records. Screening was performed by a single reviewer with artificial intelligence assistance and without independent duplicate screening, but all screening decisions and extracted data were verified by two reviewers. The evidence was synthesized by theme without a formal risk-of-bias tool. In this review, serious events reported after vaccination clustered in adults aged 65 years and older. An exploratory calculation from passive surveillance data suggested a crude reporting rate in older adults roughly seven times that in younger recipients (ratio of reporting rates about 6.9; exact 95% confidence interval 3.0 to 17.5; a reporting ratio, not a relative risk). A second exploratory calculation indicated that the pivotal trial had roughly a 25% to 40% chance of recording even one such event among its older participants, so the pre-licensure data could not have excluded a rare, age-specific signal. Age restriction appears to be the most direct safeguard currently available, although older adults remain at increased risk of severe chikungunya and no comparative data show that an age limit prevents events. Passive surveillance, a single database, manufacturer-affiliated sources, and single-screener, artificial intelligence-assisted screening limit these findings. Age-restricted use, active pharmacovigilance within the Brazilian pilot, and evaluation of the virus-like particle vaccine for older adults deserve priority.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-18
DOI
https://doi.org/10.7759/cureus.119891
Primary Topic
Mosquito-borne diseases and control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-licensure Safety of the Live-Attenuated Chikungunya Vaccine in Older Adults: An Integrative Review With Implications for Brazil

Maria Eduarda de Sá, Victória Pacheco Dirane, Bernardo Gomes Castelo Branco, Gustavo Coachman Hollenstein et al.
7 links
Cureus
Mosquito-borne diseases and control
article

Post-licensure Safety of the Live-Attenuated Chikungunya Vaccine in Older Adults: An Integrative Review With Implications for Brazil

Maria Eduarda de Sá, Victória Pacheco Dirane, Bernardo Gomes Castelo Branco, Gustavo Coachman Hollenstein, Bruno Kavahara Yoshida, Rafael Binotto Bauer, Isabella Van Der Ven, Heloisa Bertiê Silvestrini, Letícia Braz Machado, Ludmilla Carrijo Pires, Eric Correa Artero
article en

Abstract

Post-licensure reports of serious adverse events in older adults have raised concern about the live-attenuated chikungunya vaccine, which is being used in a pilot program in Brazil. This integrative review synthesizes the post-licensure safety evidence for this vaccine in older adults and discusses what it means for Brazilian policy. A single database, PubMed, was searched on 8 October 2026 for records published from 2023 onward (70 records identified and 30 included). Regulatory documents and press reports were consulted separately as supplementary sources and are not counted among the 30 records. Screening was performed by a single reviewer with artificial intelligence assistance and without independent duplicate screening, but all screening decisions and extracted data were verified by two reviewers. The evidence was synthesized by theme without a formal risk-of-bias tool. In this review, serious events reported after vaccination clustered in adults aged 65 years and older. An exploratory calculation from passive surveillance data suggested a crude reporting rate in older adults roughly seven times that in younger recipients (ratio of reporting rates about 6.9; exact 95% confidence interval 3.0 to 17.5; a reporting ratio, not a relative risk). A second exploratory calculation indicated that the pivotal trial had roughly a 25% to 40% chance of recording even one such event among its older participants, so the pre-licensure data could not have excluded a rare, age-specific signal. Age restriction appears to be the most direct safeguard currently available, although older adults remain at increased risk of severe chikungunya and no comparative data show that an age limit prevents events. Passive surveillance, a single database, manufacturer-affiliated sources, and single-screener, artificial intelligence-assisted screening limit these findings. Age-restricted use, active pharmacovigilance within the Brazilian pilot, and evaluation of the virus-like particle vaccine for older adults deserve priority.

Cureus
Universidade Nove de Julho (BR), Faculdade São Leopoldo Mandic (BR)
Good health and well-being
Mosquito-borne diseases and control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon